###### Strengths and limitations of this study

-   This is a prospectively designed study that collected information from a multinational clinical trial.

-   Unknown potential confounders may limit interpretation.

-   High quality data and patient details available.

-   Generalisability may be limited as this study was done as part of a pragmatic clinical trial.

Introduction {#s1}
============

Heart failure (HF) is a major cause of death and disability. This is especially evident in the emergency department (ED), which continues to be the primary location where patients receive care prior to hospital admission, or are discharged. Additionally, since the acute setting of the ED serves as the initial point of entry for newly diagnosed HF, patient data pertaining to this event is important to explore.

Whereas there is extensive information in acute myocardial infarction (MI) trials, registries and population health data sets regarding the use of the ambulance,[@R1] [@R2] there is little describing the mode of presentation (either ambulance or self-present) in acute HF (AHF). In patients with acute MI, extensive networks and resources as well as public health initiatives have been developed to enhance and improve the use of ambulance services. Patients with acute MI using ambulance services are at higher baseline risk and higher risk for subsequent short-term (eg, 30-day) clinical events.

Data from Canadian patients enrolled in Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) showed that 27% of trial and 52% of registry patients arrived by ambulance.[@R3] Other population health data have also shown that 50% of patients admitted to hospital for AHF arrive via ambulance, and although associated with other high-risk features, ambulance arrival independently predicted early mortality.[@R4] However, uncertainty exists with respect to the use of emergency services across a broader group of patients including those that utilise an emergency service call as the start of their healthcare encounter. Furthermore, there has been no description of the detailed timeline of care provided from symptom onset through hospital admission of patients with AHF that would mirror information available on patients with acute MI.

Accordingly, we designed a substudy to collect prehospital data on individuals enrolled in the ASCEND-HF trial. We hypothesised that patients who presented via ambulance would be at higher risk for early mortality after controlling for patient-related factors. We further describe the relationship of mode of presentation on the clinical outcomes including mortality, rehospitalisation and dyspnoea.

Methods {#s2}
=======

Study design {#s2a}
------------

The study design and results of the ASCEND-HF trial have been previously published.[@R2] [@R5] Briefly, the ASCEND-HF study evaluated nesiritide versus placebo in 7007 patients with acute decompensated HF (ADHF) enrolled within 24 h of first intravenous HF-related treatment. Participants were required to have each of the following at time of randomisation: dyspnoea at rest or with minimal activity; ≥1 accompanying sign (respiratory rate ≥20 breaths/min or pulmonary congestion/oedema with rales ≥1/3 base); and ≥1 objective measure of HF (evidence of congestion/oedema on chest X-ray; B-type natriuretic peptide (BNP) ≥400 pg/mL or *N*-terminal pro-BNP ≥1000 pg/mL; pulmonary capillary wedge pressure \>20 mm Hg; or left ventricular ejection fraction \<40% in the previous 12 months). There was no requirement for patients to have presented via emergency services (eg, ambulance) or self-present, but all patients had to be admitted to hospital for treatment of the ADHF.

Early process of care substudy design {#s2b}
-------------------------------------

Patients in the prospectively planned early process of care substudy were enrolled between April 2009 and August 2010 at 206 sites in Canada and the USA. Patients from outside North America were also eligible but based on differences in the structure and organisation of emergency medical services (EMS), inconsistent data capture and enrolment into this substudy, these patients (n=1742) were excluded from further analysis. The patients were required to provide written informed consent for the ASCEND-HF trial.

Sites were asked to provide information on whether or not patients had called emergency services (eg, 911, 000, 112), and if they arrived via ambulance or self-presented (SP; eg, walk-in, come by private vehicle or public transit). Additional information was collected on time from symptom onset, hospital or ED contact, first laboratory work and time of admission. Length of stay and other times were captured in the main case report form. Symptom onset was defined as the date and time of the qualifying HF event. Hospital arrival time was defined as when the patient arrived to the ED. Time to first medication was defined as when the study drug or placebo infusion was started. Most patients (n=960, 89.9%) received an intravenous diuretic after presentation to the ED and before the study drug; however, the times were not recorded.

Statistical analysis {#s2c}
--------------------

The aim of this study was to compare two groups of patients: those who presented by ambulance versus SP. Baseline characteristics for the selected cohort were tabulated according to presentation groups. Categorical variables were summarised through percentages and continuous variables by median and IQR for each presentation groups separately. Wilcoxon rank-sum test was applied to test the unadjusted differences between groups for continuous variables, and the χ^2^ test for the discrete variables.

The relationship between the mode of presentations and outcomes (both short term and long term) was explored through multivariable analysis. Multivariable logistic regression and Cox proportional hazard models were applied for short-term (30-day) and long-term (31-day to 180-day) outcomes, respectively. The model for 30-day all-cause death was adjusted for age, blood urea nitrogen (BUN), sodium, qualifying episode of dyspnoea and systolic blood pressure (SBP) from baseline. Both models for composite event of 30-day death or HF rehospitalisation and 31-day to 180-day death were adjusted based on age, BUN, creatinine clearance, sodium, qualifying episode of dyspnoea, SBP at baseline; and history of cerebrovascular disease, depression, HF, chronic respiratory disease. The adjusted list of covariates was validated through the ASCEND-HF risk model.[@R7] Dyspnoea, measured using a Likert scale, at 6 and 24 h was compared using the same methods as the overall trial.[@R8] [@R9]

All the statistical tests have been performed two-sided with p\<0.05 indicating statistical significance with SAS software, V.9.3 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Of the 7007 patients in ASCEND-HF, 4075 were enrolled before the substudy started to collect data, of which 2081 patients were enrolled in North America ([figure 1](#BMJOPEN2015010201F1){ref-type="fig"}). Compared with the patients enrolled prior to the substudy in North America, there were no clinically important differences (see [e-appendix, e-table](#SM1){ref-type="supplementary-material"} 1). Among the cohort of 1068 patients in the substudy, 832 patients SP and 236 patients presented via ambulance or other emergency services.
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![Cohort diagram for Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) substudy.](bmjopen2015010201f01){#BMJOPEN2015010201F1}

Patients presenting by ambulance were more likely to be female, were older, weighed less and had a higher ejection fraction than those who SP ([table 1](#BMJOPEN2015010201TB1){ref-type="table"}). The use of implantable cardioverter-defibrillators (ICDs), β-blockers and aldosterone antagonists was lower in patients presenting by ambulance, but ACE inhibitor or angiotensin receptor blocker use was similar to those who SP. Haemoglobin levels were lower in patients presenting via ambulance compared with those SP. Natriuretic peptide levels were numerically (but not statistically) lower in patients presenting via ambulance compared with those SP.

###### 

Baseline characteristics

  Variable                                Total (n=1068)      SP (n=832)          EMS (n=236)         p Value
  --------------------------------------- ------------------- ------------------- ------------------- ---------
  Demographics                                                                                        
   Female (%)                             35                  33                  44                  0.003
   Age (years)                            67 (55, 78)         65 (55, 77)         72 (61, 81)         \<0.001
   Weight (kg)                            87 (73, 106)        89 (74, 109)        83 (72, 102)        0.001
  Race (%)                                0.641                                                       
   White                                  61                  62                  58                  
   Black                                  34                  33                  36                  
   Asian                                  2                   2                   2                   
   Other                                  3                   3                   4                   
  Past medical history (%)                                                                            
   Hospitalised for HF in the last year   46                  45                  48                  0.397
   Ischaemic aetiology of HF              60                  60                  61                  0.748
   Prior myocardial infarction            35                  35                  36                  0.604
   Diabetes mellitus                      49                  49                  50                  0.744
   Hypertension                           83                  81                  88                  0.017
   Atrial fibrillation                    42                  43                  38                  0.159
   ICD                                    17                  19                  12                  0.012
   Biventricular pacemaker                1.3                 1.6                 0.4                 0.175
   COPD                                   27                  26                  29                  0.403
   Depression                             12                  12                  12                  0.970
  Physical examination                                                                                
   Systolic blood pressure (mm Hg)        126 (111, 140)      124 (110, 140)      130 (116, 140)      0.003
   Diastolic blood pressure (mm Hg)       74 (65, 84)         74 (65, 85)         72 (64, 84)         0.477
   Heart rate at rest (bpm)               79 (69, 90)         79 (70, 90)         78 (69, 90)         0.616
   Respiratory rate (breaths/min)         22 (20, 24)         22 (20, 24)         22 (20, 24)         0.003
  Investigations                                                                                      
   Creatinine (μmol/L)                    115 (90, 145)       115 (90, 143)       115 (95, 149)       0.816
   BNP (pg/mL)                            1020 (618, 1822)    1036 (633, 1869)    986 (577, 1752)     0.244
   NT-pro-BNP                             4792 (2661, 9355)   5043 (2642, 9398)   3920 (2955, 7492)   0.797
   Haemoglobin (g/dL)                     123 (110, 135)      124 (110, 136)      120 (108, 133)      0.034
   Sodium (mmol/L)                        139 (137, 141)      139 (136, 141)      139 (137, 141)      0.111
   Ejection fraction (%)                  28 (20, 40)         25 (20, 40)         33 (21, 50)         \<0.001
  Medications (%)                                                                                     
   ACE inhibitor or ARB\*                 63                  64                  62                  0.605
   β-blocker\*                            74                  76                  67                  0.009
   Aldosterone antagonists\*              23                  25                  15                  0.001
   Nitrates (oral or topical)\*           24                  24                  26                  0.542
   Inotropes                              2                   2                   2                   0.554
   Vasodilators                           3                   2                   7                   \<0.001
   Use of study drug bolus                55                  51                  70                  \<0.001

Values are median (q1, q3) unless otherwise stated.

\*Medications prior to hospitalisation.

ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; EMS, emergency medical services; HF, heart failure; ICD, implantable cardioverter-defibrillator; NT-pro-BNP, *N*-terminal pro-BNP; SP, self-presented.

Patients presented to hospital a median of 26.1 h after symptom onset (IQR 1.4--130.3 h) and this tended to be shorter for patients who presented by ambulance (median 22.7 h (IQR 1.5--71.1 h)) compared with those who SP (median 28.7 h (IQR 1.4--152.3 h; p=0.06)). Patients underwent randomisation into the ASCEND-HF trial a median of 45.2 h after symptom onset (IQR 21.3--148.3 h), and this was shorter for patients presenting by ambulance (39.4 h (IQR 17.5--88.2 h)) compared with patients who SP (47.8 h (IQR 21.7--169.8 h; p=0.02)). Accordingly, patients who arrived by ambulance had a shorter time from hospital presentation to randomisation (14.7 h (IQR 8.7--23.4 h)) than those who SP (18.7 h (IQR 7.5--22.7 h); p=0.87).

Patients arrived on weekdays (88.5%) and weekends (11.5%) and this differed according to mode of presentation (SP: 89.5% weekdays, 10.5% weekends; ambulance: 84.8% weekdays, 15.2% weekends; p=0.04). Additionally, more patients in the SP group arrived during daytime hours (74.5%) compared with those arriving by ambulance (50.9%, p≤0.01).

Clinical outcomes {#s3a}
-----------------

Patients in the substudy had a 30-day and 180-day mortality rate of 2.6% and 11.3%, respectively, and this was similar to the overall ASCEND-HF study. Patients who presented by ambulance had a higher 30-day and 180-day mortality rate than those who SP (30-day: 4.3% vs 2.2%, p=0.08; 180-day: 15.1% vs 10.3%, p=0.04). The co-primary end point of the ASCEND-HF trial of 30-day mortality or HF rehospitalisation was similar between groups (ambulance 12.2% vs SP 11.4%, p=0.74). The index hospitalisation length of stay was similar between the ambulance and SP groups (p=0.53). Patients presenting by ambulance (compared with those self-presenting) had similar dyspnoea improvement at 6 (p=0.48) and 24 h (p=0.20; [figure 2](#BMJOPEN2015010201F2){ref-type="fig"}).

![Self-assessed dyspnoea at 6 and 24 h according to mode of presentation. EMS, emergency medical services; SP, self-presented.](bmjopen2015010201f02){#BMJOPEN2015010201F2}

Multivariable analysis {#s3b}
----------------------

Using the ASCEND-HF model to adjust for baseline characteristics, patients arriving by ambulance had a twofold high risk of 30-day mortality (OR 2.12, 95% CI 0.94 to 4.79), a trend towards increased 31-day to 180-day mortality (HR 1.70, 95% CI 0.94 to 3.08) but no relationship to the composite of 30-day mortality/HF rehospitalisation (OR 1.01, 95% CI 0.63 to 1.63) when compared with those patients who are SP. When additional variables were added, including time of presentation, weekday or weekend, none of these were independently significant predictors of the above outcomes.

Discussion {#s4}
==========

In this prospectively designed substudy, we demonstrated that 22% of patients with AHF in the ASCEND-HF trial presented via ambulance. There are three principal novel observations emerging from our study: the patients presenting via ambulance: (1) are older, more likely to female and have a higher ejection fraction; (2) their risk by traditional markers including vital signs, natriuretic peptides and renal function do not differ from those who self-present; and (3) their early and adjusted mortality was twofold that of patients who self-present.

Prior studies have described the rate of ambulance use in unselected populations of patients with AHF seen in the ED. In two prior Canadian studies, between 38% and 52% of patients with AHF seen in the ED arrived via ambulance.[@R10] [@R11] In the study by Lee *et al*,[@R10] patients arriving via ambulance were at an over twofold higher risk for 7-day mortality and factor into the risk score intended to predict poor outcomes. Since an ambulance trip by itself confers (to the best of our knowledge) no direct detrimental effect, this likely reflects the patient population more likely to utilise EMS: patients who are older, socially isolated and female.

Should the mode of arrival be incorporated into patient-level decisions or triage? It is likely that this feature is confounded by the above factors in addition to cost concerns, symptom duration and availability of other modes of transport, and thus captures unmeasured confounders and patient preferences rather than actually providing a risk factor linked to the disease state. This is supported by our analysis demonstrating no difference in traditional or advanced biomarkers such as BNP, yet a twofold difference in the risk of death at 30 days.

Whether or not patients with AHF should be directed to call emergency services and be transported by an ambulance as those with acute stroke or MI are encouraged to do so via public service messages is uncertain. The prevalence of HF is high in the community,[@R12] [@R13] and thus the implications to patients, payers and providers should be considered before deploying a community-wide public health message. Additionally and since RCT-proven therapies for treating AHF are non-existent, what additional benefit will the rapid arrival, diagnosis, triage and transport have on clinical outcomes? Research involving integrated health teams equipped with the appropriate knowledge, equipment (such as rapid turn-around biomarkers including BNP) and treatments need to be systematically studied. One such randomised trial is underway testing the utility of rapid access testing of BNP in the ambulance trying to shorten the time to therapy and potentially clinical outcomes (NCT01634425, <http://www.clinicaltrials.gov>). In the ED, use of biomarkers has aided in the diagnosis of HF,[@R14] provides improved discrimination when used in diagnostic scores[@R1] and once integrated into clinical practice, is cost-effective.[@R2] [@R15]

Early trials involving therapies available prehospital for acute MI and stroke have demonstrated a reduction in early mortality or morbidity. One AHF trial using prehospital high-dose nitrates demonstrated a reduction in early adverse clinical events.[@R3] [@R16] Replication of this and other novel therapies need to be tested in appropriately designed RCT, as other therapies with an early positive signal have yet to demonstrate efficacy.[@R5] [@R6] [@R17] Additional therapy deployed early in the ED has had mixed results for vasodilators, including nesiritide.[@R9] [@R10] [@R12] [@R18] [@R19]

We present information regarding the time of day and day of week as these have been previously linked to outcomes.[@R20] In our study, while differences exist with more ambulance patients presenting at night and on the weekends, this may represent other social factors rather than a true difference in risk related to the patient. For example, patients who live alone may be unable to get to the ED at night, or on the weekends due to availability of family or friends to transport them to the ED and other factors such as patient preferences may play a role in mode of transportation.[@R21] Prehospital delay has also not been linked to clinical outcomes; however, patients with \<24 h since symptom onset have a lower BNP and a shorter length of stay.[@R22] Indeed, when added to the multivariable model, these factors were not independently significant predictors of clinical outcomes in ASCEND-HF.

Strengths and limitations {#s4a}
-------------------------

While this is a prospectively designed substudy of a high-quality RCT, certain limitations deserve mention. First, in designing the study, we recognised the difficulty in capturing information in a global trial given the substantial differences in the meaning and delivery of ambulance services in different countries (and within countries). We therefore had to limit the data presented to that of North America where services are more homogeneous. Whether similar findings are evident elsewhere in the world is uncertain. Second, we captured detail about time from symptom onset; however, patient description of symptoms and their timing may vary based on severity of symptoms, chronicity of disease, prior similar events and other unknown confounders. The sites captured this information in an identical fashion; yet, there is limited information on the other potential confounders including the trigger for needing emergent care which may vary significantly across patient groups and regions. Third, ASCEND-HF represents a more pragmatic RCT and differences may exist in non-RCT populations due to the certainty in the diagnosis of HF; however, our findings should stimulate registry and population health studies to adequately describe and report their findings.[@R11] ASCEND-HF, required signs, symptoms and an objective marker of HF to ensure that HF was present---prior validated criteria such as the Framingham,[@R23] Boston[@R24] and other criteria need validation in the current era given the improvements in understanding the clinical phenotype of HF. Fifth, ASCEND-HF required patients to be identified and subsequently consent to participate. Both of these further limit generalisability as clinical trial sites and research team members had to be available and may have approached individuals who were less symptomatic yet still requiring hospitalisation for HF. Similarly, patients who participated may have also had less overall symptom burden or risk than patients who declined participation. Finally, we present HRs with 95% CI, and for some of our outcomes, these cross the 1.0 on the lower boundary. These should be interpreted accordingly and are considered hypothesis generating in their meaning.

Conclusions {#s5}
===========

In the ASCEND-HF trial, 22% of patients presented via ambulance and these patients were older and more likely to be female, yet did not differ in other major prognostic measures such as natriuretic peptides. However, the adjusted mortality rate was twice the rate for patients presenting via ambulance than those who self-present. Understanding patient-related and system-related factors of ambulance use for patients with AHF is important. Future studies should be cautious about utilising ambulance use in risk scores.
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